The paper focuses on the possibility of practical use of intrauterine contraception containing levonorgestrel. At present
two intrauterine systems with levonorgestrel exist (LNG-IUS 52mg and LNG-IUS 13.5mg). When used, they differ namely
in the possibility to use it for nuliparas (in this group LNG-IUS 13.5mg is preferred) and in use for therapeutical purposes,
where only LNG-IUS 52mg is indicated. Despite high contraceptive reliability of both systems and proved benefit
there are still worries about possible complications even in medical community. These worries, as the paper shows,
were refuted in several studies and marked as unjustified.